Objective
to report the 1-year outcomes of percutaneous transcatheter edge-to-edge repair (TEER) for severe tricuspid regurgitation as compared to medical treatment
Study
international, multicentre, randomised trial
Population
patients with severe tricuspid regurgitation (NYHA II, III or IVa) and pulmonary artery SP <70mm Hg and at intermediate or greater surgical risk
Endpoints
hierarchical endpoint including any death, tricuspid-valve surgery, hospitalisation for heart failure and improvement in quality of life (Kansas City cardiomyopathy questionnaire) of at least 15 points at 1 year follow-up
Conclusion
Tricuspid TEER for patients with severe tricuspid regurgitation reduced the severity of tricuspid regurgitation as compared to medical treatment during 1 year follow-up
Sorajja et al NEJM 2023: March 4
